An analysis of which subgroups of multiple myeloma patients, divided according to b(2)-microglobulin and plasma cell labeling index, benefit from high dose vs conventional chemotherapy.

Source:http://linkedlifedata.com/resource/pubmed/id/10509038

Download in:

View as

General Info

PMID
10509038